You are here: Industry Insights > Zogenix

News List

UCB to buy rare disease therapies developer Zogenix for $1.9bn Pharmaceutical-Technology
January 21, 2022
The company’s subsidiary will be merged into Zogenix and the remaining shares of Zogenix common stock will be cancelled.
EU green light for Zogenix’s Fintepla pharmatimes
December 24, 2020
The European Commission (EC) has approved Zogenix’s Fintepla (fenfluramine) for the treatment of seizures associated with Dravet syndrome.
US FDA grants approval of Fintepla to Zogenix expresspharma
June 28, 2020
Fintepla offers an additional effective treatment option for the treatment of seizures associated with Dravet syndrome: Zogenix.
Zogenix Receives Refusal to File Letter from U.S. Food and Drug Administration for Fintepla New Drug Application drugs
April 18, 2019
Zogenix Receives Refusal to File Letter from U.S. Food and Drug Administration for Fintepla New Drug Application.
Shares in Zogenix plunge after FDA issues refuse-to-file letter for Fintepla as seizure treatment in Dravet syndrome firstwordpharma
April 09, 2019
Zogenix on Monday announced the receipt of a refuse-to-file letter from the FDA regarding its filing seeking approval……
Zogenix’ drug cuts seizures in Dravet syndrome pharmatimes
July 16, 2018
The study met its primary endpoint, demonstrating that the drug is superior to placebo as adjunctive therapy to stiripentol in the treatment of children and young adults with the condition, a difficult-to-treat form of childhood-onset epilepsy.
Zogenix’ drug cuts seizures in Dravet syndrome pharmatimes
July 13, 2018
Zogenix has revealed top-line results from a second late-stage trial of its investigational Dravet syndrome drug ZX008, showing a significant reduction in seizures.